MECHELEN, BELGIUM--(Marketwire - June 22, 2012) - Galapagos NV (EURONEXT BRUSSELS: GLPG)
announced today that it won the European Mediscience Awards for
Transaction of
the year and Chief Executive of the year at last night's ceremony in
London.
The Transaction of the year award recognizes the global collaboration
with
Abbott for selective JAK1 inhibitor GLPG0634. The Chief Executive of the
year
award recognizes the leadership and other qualities demonstrated by Onno
van de
Stolpe.
"We are pleased to have won two European Mediscience awards, which
also
acknowledge the efforts of the entire Galapagos team," said Dr Raj
Parekh,
Chairman of the Board of Directors of Galapagos. "Galapagos is
executing its
strategy to become a European leader in biotech, and these awards
recognize the
progress Galapagos is making toward achieving that ambition."
About the European Mediscience Awards
The European Mediscience Awards have been held since 2002 and celebrate the
best
in the quoted life science, healthcare and biotech industries. The event
has
grown to be the largest annual gathering of private and publicly quoted
healthcare, biotech and life science companies in Europe, attracting over
500
attendees. More info at: www.mediscience-event.co.uk
About Galapagos
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size
biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634,
as
well as one of the largest pipelines in biotech, with four programs in
development and over 30 discovery programs. The Galapagos Group has about
800
employees and operates facilities in six countries, with global
headquarters in
Mechelen, Belgium. More info at: www.glpg.com
This release may contain forward-looking statements, including,
without
limitation, statements containing the words "believes,"
"anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
performance
or achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions,
performance or
achievements expressed or implied by such forward-looking statements.
Given
these uncertainties, the reader is advised not to place any undue
reliance on
such forward-looking statements. These forward-looking statements speak
only as
of the date of publication of this document. Galapagos expressly
disclaims any
obligation to update any such forward-looking statements in this
document to
reflect any change in its expectations with regard thereto or any
change in
events, conditions or circumstances on which any such statement is based,
unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1621438]
